For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Amylyx Pharmaceuticals Inc’s stock clocked out at $15.17, down -3.93% from its previous closing price of $15.79. In other words, the price has decreased by -$3.93 from its previous closing price. On the day, 1.64 million shares were traded. AMLX stock price reached its highest trading level at $15.93 during the session, while it also had its lowest trading level at $14.87.
Ratios:
To gain a deeper understanding of AMLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.72 and its Current Ratio is at 8.72. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On June 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $17.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on June 17, 2025, with a $12 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 30 ’25 when Klee Justin B. sold 29,975 shares for $14.38 per share. The transaction valued at 430,952 led to the insider holds 3,325,301 shares of the business.
Mazzariello Gina sold 8,828 shares of AMLX for $128,669 on Sep 30 ’25. The Chief Legal Officer now owns 148,141 shares after completing the transaction at $14.58 per share. On Sep 30 ’25, another insider, FRATES JAMES M, who serves as the Chief Financial Officer of the company, sold 10,558 shares for $14.65 each. As a result, the insider received 154,650 and left with 280,430 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1618144896 and an Enterprise Value of 1177805952. Its current Enterprise Value per Revenue stands at -4730.144 whereas that against EBITDA is -6.0.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.34, which has changed by 3.0280614 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $15.94, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is 33.32%, while the 200-Day Moving Average is calculated to be 134.57%.
Shares Statistics:
It appears that AMLX traded 1.64M shares on average per day over the past three months and 1956340 shares per day over the past ten days. A total of 89.16M shares are outstanding, with a floating share count of 84.11M. Insiders hold about 25.30% of the company’s shares, while institutions hold 70.84% stake in the company. Shares short for AMLX as of 1759190400 were 10066534 with a Short Ratio of 6.14, compared to 1756425600 on 8410918. Therefore, it implies a Short% of Shares Outstanding of 10066534 and a Short% of Float of 10.24.
Earnings Estimates
. The current assessment of Amylyx Pharmaceuticals Inc (AMLX) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.06 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.17 and -$2.02 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.37, with 7.0 analysts recommending between -$0.76 and -$2.05.
